![Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace](https://mms.businesswire.com/media/20180914005613/en/678526/4/AJOVY+Image.jpg)
Teva Announces U.S. Approval of AJOVYTM (fremanezumab-vfrm) Injection, the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Preventive Treatment of Migraine in Adults ADDING MULTIMEDIA | BioSpace
![Omeprazole Generic Drug Box by Teva Closeup Against White Editorial Image - Image of american, generics: 187803275 Omeprazole Generic Drug Box by Teva Closeup Against White Editorial Image - Image of american, generics: 187803275](https://thumbs.dreamstime.com/b/kyiv-ukraine-may-gastroenterology-generic-drug-omeprazole-teva-box-closeup-white-teva-pharmaceuticals-american-israeli-187803275.jpg)
Omeprazole Generic Drug Box by Teva Closeup Against White Editorial Image - Image of american, generics: 187803275
![Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter | FDA Teva Issues Voluntary Nationwide Recall of One Lot of IDArubicin Hydrochloride Injection USP 5 mg/5 mL Due to the Presence of Particulate Matter | FDA](https://www.fda.gov/files/styles/recall_image_small/public/image-1_53.png?itok=-VZ3-Pnq)